Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study on bacterial infection in older individuals

The older population is prone to microbial infections, which can lead to death. Hence, it is important to understand why this group is vulnerable to microbial infection, especially bacterial infection. A recent Scientific Reports study linked data from two sources to understand the determining factors for microbial infection in the older population in the UK.

11 Jan 2023

COVID-19 outcomes in Rituximab treated patients

A new report throws light on SARS-CoV-2 breakthrough infections in patients with certain joint diseases or musculoskeletal conditions who are on rituximab and compares the severity of COVID-19 outcomes in these patients whilst identifying potential risk factors for severe outcomes.

11 Jan 2023

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

A recent study used generative AI models to develop de novo design antibodies against three distinct targets in a zero-shot fashion.

11 Jan 2023

New analysis improves the scientific community's understanding of COVID-19 immunity

A new analysis by Cedars-Sinai investigators is furthering the scientific community's understanding of COVID-19 immunity by showing that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups.

11 Jan 2023

Protein Medin: A new treatment target for Alzheimer's

A recent study published in the journal Nature reported the co-aggregation of medin, a fragment of lactadherin, with vascular amyloid-β in Alzheimer’s disease (AD).

10 Jan 2023

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor.

10 Jan 2023

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

In a recent correspondence published in The Lancet Infectious Diseases journal, researchers in Germany assessed the neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB.1 lineage.

9 Jan 2023

Deletions in the antigenic regions in SARS-CoV-2 increase transmission and immune evasion ability

A recent study published in the journal Scientific Reports examined the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole genome data to determine the deletion mutations around the spike protein region associated with increased transmission of the virus and identified an increase in the deletion-prone spike protein regions indicating an evolution strategy for immune escape.

9 Jan 2023

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

9 Jan 2023

Study reveals poor immunity against SARS-CoV-2 BQ.1.1 and XBB mutants in Norway

Researchers conducted a seroprevalence study in the general population of Norway, evaluating immunity against multiple subvariants of SARS-CoV-2 Omicron, including XBB and BQ.1.1 mutants.

9 Jan 2023

Research suggests people on rheumatoid arthritis drugs show weaker response to SARS-CoV-2 vaccines

Researchers conducted a comparative study among a cohort of individuals on rheumatoid arthritis (RA) therapies vis-à-vis healthy controls to assess their responses to coronavirus disease 2019 (COVID-19) vaccines.

9 Jan 2023

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

8 Jan 2023

Does the duration between SARS-CoV-2 infection and vaccination affect immunity?

In a recent study posted to the medRxiv* preprint server, researchers at Oregon Health & Science University assessed the impact of the duration between coronavirus disease 2019 (COVID-19) infection and vaccination on immunity against infection.

8 Jan 2023

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

A new study aimed to analyze whether the order of immunization of vaccine types impacted the efficacy of a heterologous prime-boost vaccination strategy.

6 Jan 2023

Study shows XBB.1.5 exhibits a substantially higher hACE2-binding affinity compared to BQ.1.1 and XBB/XBB.1

Researchers investigated the reasons for the rapid advent of SARS-CoV-2 XBB.1.5, a sublineage of the Omicron recombinant mutant XBB in the USA.

6 Jan 2023

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.

6 Jan 2023

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

5 Jan 2023

Seroprevalence study demonstrates vaccination could boost impaired humoral immunity against Omicron BQ.1.1 subvariant

Researchers conducted a multicenter, cross-sectional seroprevalence study in emergency departments of five hospitals in North Rhine-Westphalia, Germany, between August and September 2022. They assessed point seroprevalence and neutralization activity against Wu01, BA.4/5, and BQ.1.1.

5 Jan 2023

Longitudinal seroprevalence study among pregnant people indicates waning of immunity from natural SARS-CoV-2 infections

Researchers evaluated the seroprevalence and durability of antibodies against SARS-CoV-2 nucleocapsid protein among pregnant individuals and investigated transplacental antibody transfer.

3 Jan 2023

What is the global state of SARS-CoV-2 seroprevalence in children?

Researchers conducted a systematic review to assess global pediatric SARS-CoV-2 seroprevalence.

3 Jan 2023

Antibody News and Research

Further Reading

Study on bacterial infection in older individuals

COVID-19 outcomes in Rituximab treated patients

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

New analysis improves the scientific community's understanding of COVID-19 immunity

Protein Medin: A new treatment target for Alzheimer's

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

Deletions in the antigenic regions in SARS-CoV-2 increase transmission and immune evasion ability

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Study reveals poor immunity against SARS-CoV-2 BQ.1.1 and XBB mutants in Norway

Research suggests people on rheumatoid arthritis drugs show weaker response to SARS-CoV-2 vaccines

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

Does the duration between SARS-CoV-2 infection and vaccination affect immunity?

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

Study shows XBB.1.5 exhibits a substantially higher hACE2-binding affinity compared to BQ.1.1 and XBB/XBB.1

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

Seroprevalence study demonstrates vaccination could boost impaired humoral immunity against Omicron BQ.1.1 subvariant

Longitudinal seroprevalence study among pregnant people indicates waning of immunity from natural SARS-CoV-2 infections

What is the global state of SARS-CoV-2 seroprevalence in children?

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo